October 2, 2017 – Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
West Lafayette, Ind., Oct. 2, 2017 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyte intends to move quickly into Phase 3 development of 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC).
April 26, 2017 – In the News – Food and Drug Administration (FDA) Approves the First Deuterated Drug, AUSTEDO™ by Teva
Cambridge Isotope Laboratories, Inc. is pleased that the Food and Drug Administration (FDA) approved the first deuterated drug, AUSTEDO™ by Teva (previously referred to as SD-809).